Special Issue "B Cell Lymphoma in the Spleen"
Deadline for manuscript submissions: 10 October 2021.
Malignant lymphoma in the spleen may be primary (usually designated as splenic lymphoma) or secondary (due to progression of nodal or extra nodal lymphoproliferative disease), and represents an underestimated cause of splenomegaly, since splenectomy is seldom performed. Lymphomatous involvement of the spleen represents widely heterogenous clinicopathologic features, ranging from indolent to highly aggressive disease, which still represent a therapeutic challenge. Biologically, any hematopoietic cell lineage may represent the cell of origin. However, low grade B cell lymphomas probably represent the vast majority of incurable cases and are, therefore, the subject of this review series.
Through a series of papers, we will describe the most common entities based on the approach of the WHO classification of tumors integrating clinical, morphological, immunophenotypical, and molecular characteristics to review the current therapeutic modalities.
This Special Issue would include, but not be limited to, the following topics: CD5-positive B cell lymphoma, CD10-positive B cell lymphoma, CD5/CD10-double negative B cell lymphoma, and primary splenic lymphoma.
A practical emphasis on establishing a differential diagnosis and choosing the most appropriate therapy based on current molecular profiling will be made.
In summary, we will provide a state-of-the-art review on B cell lymphomas in the spleen that clinicians, pathologists, and basic science investigators may find informative.
Dr. Victor E. Nava
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.